±«ÓãÖ±²¥

Quarterly report pursuant to Section 13 or 15(d)

EARNINGS PER SHARE

v3.20.2
EARNINGS PER SHARE
6 Months Ended
Sep. 26, 2020
Earnings Per Share [Abstract] Ìý
EARNINGS PER SHARE EARNINGS PER SHARE
Ìý Three Months Ended September Six Months Ended September
(In thousands, except per share amounts) 2020 2019 2020 2019
Earnings (loss) per share – basic:
Income (loss) from continuing operations
$ 243,246Ìý $ 625,377Ìý $ (34,496) $ 690,650Ìý
Weighted average common shares outstanding
389,219Ìý 397,751Ìý 388,957Ìý 397,239Ìý
Earnings (loss) per share from continuing operations
$ 0.62Ìý $ 1.57Ìý $ (0.09) $ 1.74Ìý
Earnings (loss) per share – diluted:
Income (loss) from continuing operations
$ 243,246Ìý $ 625,377Ìý $ (34,496) $ 690,650Ìý
Weighted average common shares outstanding
389,219Ìý 397,751Ìý 388,957Ìý 397,239Ìý
Incremental shares from stock options and other dilutive securities
1,961Ìý 4,510Ìý 2,029Ìý 4,849Ìý
Adjusted weighted average common shares outstanding
391,180Ìý 402,261Ìý 390,986Ìý 402,088Ìý
Earnings (loss) per share from continuing operations
$ 0.62Ìý $ 1.55Ìý $ (0.09) $ 1.72Ìý
Outstanding options to purchase approximately 5.4 million shares were excluded from the calculations of diluted earnings per share for both the three and six-month periods ended September 2020, and outstanding options to purchase approximately 1.5 million shares were excluded from the calculations of diluted earnings per share for both the three and six-month periods ended September 2019, because the effect of their inclusion would have been anti-dilutive. In addition, 0.8 million and 0.6 million shares of performance-based RSUs were excluded from the calculations of diluted earnings per share for the three and six-month periods ended September 2020, respectively, and 0.8 million shares of performance-based RSUs were excluded from the calculations of diluted earnings per share for both the three and six-month periods ended September 2019, because these units were not considered to be contingent outstanding shares in those periods.